Personal neoantigen cancer vaccines: The momentum builds
MetadataShow full item record
CitationFritsch, Edward F, Nir Hacohen, and Catherine J Wu. 2014. “Personal neoantigen cancer vaccines: The momentum builds.” Oncoimmunology 3 (1): e29311. doi:10.4161/onci.29311. http://dx.doi.org/10.4161/onci.29311.
AbstractNeoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient’s tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstanding questions and desired further improvements, neoantigen vaccines are currently undergoing clinical evaluation.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:12785970
- HMS Scholarly Articles